Richard Gregory, Ph.D., is the Executive Vice President and Chief Scientific Officer of ImmunoGen. He joined ImmunoGen in 2015 bringing over 25 years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. His group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation in CFTR. In 1990 Dr. Gregory founded the Gene Therapy program at Genzyme and was Vice President for Gene Therapy until 2003. In 2003, he was appointed Senior Vice President and Head of Research at Genzyme, with responsibility for early research “from discovery to development” for all Genzyme therapeutic areas, including rare diseases, oncology, renal and immunology. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Gregory was appointed Head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval. He received his doctorate in biochemistry from the University of Massachusetts at Amherst, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology.